國立虎尾科技大學 |

Idiopathic Pulmonary Fibrosis = Advances in Diagnostic Tools and Disease Management /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Idiopathic Pulmonary Fibrosis/ edited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
Reminder of title:	Advances in Diagnostic Tools and Disease Management /
other author:	Nakamura, Hiroyuki.
Description:	X, 259 p.online resource. :
Contained By:	Springer Nature eBook
Subject:	Respiratory organs—Diseases. -
Online resource:	https://doi.org/10.1007/978-4-431-55582-7
ISBN:	9784431555827

Idiopathic Pulmonary Fibrosis = Advances in Diagnostic Tools and Disease Management /
Idiopathic Pulmonary FibrosisAdvances in Diagnostic Tools and Disease Management /[electronic resource] :edited by Hiroyuki Nakamura, Kazutetsu Aoshiba. - 1st ed. 2016. - X, 259 p.online resource.

Part 1 -- Definition, epidemiology, and pathogenesis -- Chapter 1: Definition of IPF (Question: Is the latest classification [ATS/ERS] satisfactory?) -- Chapter 2: Epidemiology and risk factors of IPF (Question: Can we dare to ask, “What are the possible causes?”) -- Chapter 3: Acute exacerbation of IPF (Question: The concept was proposed in Japan, but why was it not recognized in western countries?) -- Chapter 4: Pathogenesis (Question: Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease?) -- Part 2 Diagnosis -- Chapter 5: Specific serum markers of IPF (Question: What are the significances of KL-6, SP-A, and SP-D?) -- Chapter 6: High-resolution CT of honeycombing and IPF/UIP (Question: To what extent can honeycomb lung be diagnosed by imaging? To what extent can IPF diagnosis be made by HRCT?) -- Chapter 7: Pathology of IPF (Question: Why does the pathological classification of IIPs vary among pathologists?) -- Chapter 8: Differential diagnosis (Question: What should we particularly keep in mind in the differential diagnosis?) -- Part 3 Management and prognosis -- Chapter 9 Pharmacotherapy of IPF (antifibrotic compounds) (Question: Can antifibrotic agents really inhibit fibrosis? How about the development of new therapeutic agents?) -- Chapter 10: Pharmacotherapy of IPF (Corticosteroids, immunosuppressants) (Question: Are these actually effective? Ineffective? Harmful?) -- Chapter 11: Non-pharmacological therapy for IPF (Question: Is respiratory care actually effective?) -- Chapter 12: Pharmacotherapy of acute exacerbation of IPF (Corticosteroids, immunosuppressants and direct hemoperfusion with polymyxin B) (Question: Are high-dose steroid therapy, other immunosuppressant therapy, and PMX therapy [often used in Japan] really effective?) -- Part 4 Topics -- Chapter 13 :Combined pulmonary fibrosis and emphysema (CPFE) (Question: Is it an independent disease entity?) -- Chapter 14: Common pathways in IPF and lung cancer (Question: Why is lung cancer associated with IPF at a high frequency?) -- Chapter 15 :Acute exacerbation of IIPs after pulmonary resection for lung cancer (Question: Can acute exacerbation of IPF be predicted preoperatively?) .

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.

ISBN: 9784431555827

Standard No.: 10.1007/978-4-431-55582-7doiSubjects--Topical Terms:

1254083
Respiratory organs—Diseases.

LC Class. No.: RC705-779

Dewey Class. No.: 616.2

Idiopathic Pulmonary Fibrosis = Advances in Diagnostic Tools and Disease Management /
LDR:04852nam a22003975i 4500 001 973931
003 DE-He213
005 20200702091915.0
007 cr nn 008mamaa
008 201211s2016 ja | s |||| 0|eng d
020 $a 9784431555827 $9 978-4-431-55582-7
024 7 $a 10.1007/978-4-431-55582-7 $2 doi
035 $a 978-4-431-55582-7
050 4 $a RC705-779
072 7 $a MJL $2 bicssc
072 7 $a MED079000 $2 bisacsh
072 7 $a MJL $2 thema
082 0 4 $a 616.2 $2 23
245 1 0 $a Idiopathic Pulmonary Fibrosis $h [electronic resource] : $b Advances in Diagnostic Tools and Disease Management / $c edited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
250 $a 1st ed. 2016.
264 1 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2016.
300 $a X, 259 p. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Part 1 -- Definition, epidemiology, and pathogenesis -- Chapter 1: Definition of IPF (Question: Is the latest classification [ATS/ERS] satisfactory?) -- Chapter 2: Epidemiology and risk factors of IPF (Question: Can we dare to ask, “What are the possible causes?”) -- Chapter 3: Acute exacerbation of IPF (Question: The concept was proposed in Japan, but why was it not recognized in western countries?) -- Chapter 4: Pathogenesis (Question: Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease?) -- Part 2 Diagnosis -- Chapter 5: Specific serum markers of IPF (Question: What are the significances of KL-6, SP-A, and SP-D?) -- Chapter 6: High-resolution CT of honeycombing and IPF/UIP (Question: To what extent can honeycomb lung be diagnosed by imaging? To what extent can IPF diagnosis be made by HRCT?) -- Chapter 7: Pathology of IPF (Question: Why does the pathological classification of IIPs vary among pathologists?) -- Chapter 8: Differential diagnosis (Question: What should we particularly keep in mind in the differential diagnosis?) -- Part 3 Management and prognosis -- Chapter 9 Pharmacotherapy of IPF (antifibrotic compounds) (Question: Can antifibrotic agents really inhibit fibrosis? How about the development of new therapeutic agents?) -- Chapter 10: Pharmacotherapy of IPF (Corticosteroids, immunosuppressants) (Question: Are these actually effective? Ineffective? Harmful?) -- Chapter 11: Non-pharmacological therapy for IPF (Question: Is respiratory care actually effective?) -- Chapter 12: Pharmacotherapy of acute exacerbation of IPF (Corticosteroids, immunosuppressants and direct hemoperfusion with polymyxin B) (Question: Are high-dose steroid therapy, other immunosuppressant therapy, and PMX therapy [often used in Japan] really effective?) -- Part 4 Topics -- Chapter 13 :Combined pulmonary fibrosis and emphysema (CPFE) (Question: Is it an independent disease entity?) -- Chapter 14: Common pathways in IPF and lung cancer (Question: Why is lung cancer associated with IPF at a high frequency?) -- Chapter 15 :Acute exacerbation of IIPs after pulmonary resection for lung cancer (Question: Can acute exacerbation of IPF be predicted preoperatively?) .
520 $a From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.
650 0 $a Respiratory organs—Diseases. $3 1254083
650 0 $a Cytokines. $3 581465
650 0 $a Growth factors. $3 872208
650 1 4 $a Pneumology/Respiratory System. $3 668561
650 2 4 $a Cytokines and Growth Factors. $3 787581
700 1 $a Nakamura, Hiroyuki. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1103255
700 1 $a Aoshiba, Kazutetsu. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1103256
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9784431555810
776 0 8 $i Printed edition: $z 9784431555834
776 0 8 $i Printed edition: $z 9784431562818
856 4 0 $u https://doi.org/10.1007/978-4-431-55582-7
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)